Literature DB >> 21993676

A survey on hematology-oncology pediatric AIEOP centers: prophylaxis, empirical therapy and nursing prevention procedures of infectious complications.

Susanna Livadiotti1, Giuseppe Maria Milano, Annalisa Serra, Laura Folgori, Alessandro Jenkner, Elio Castagnola, Simone Cesaro, Mario R Rossi, Angelica Barone, Giulio Zanazzo, Francesca Nesi, Maria Licciardello, Raffaella De Santis, Ottavio Ziino, Monica Cellini, Fulvio Porta, Desiree Caselli, Giuseppe Pontrelli.   

Abstract

A nationwide questionnaire-based survey was designed to evaluate the management and prophylaxis of febrile neutropenia in pediatric patients admitted to hematology-oncology and hematopoietic stem cell transplant units. Of the 34 participating centers, 40 and 63%, respectively, continue to prescribe antibacterial and antimycotic prophylaxis in low-risk subjects and 78 and 94% in transplant patients. Approximately half of the centers prescribe a combination antibiotic regimen as first-line therapy in low-risk patients and up to 81% in high-risk patients. When initial empirical therapy fails after seven days, 63% of the centers add empirical antimycotic therapy in low-and 81% in high-risk patients. Overall management varies significantly across centers. Preventive nursing procedures are in accordance with international guidelines. This survey is the first to focus on prescribing practices in children with cancer and could help to implement practice guidelines.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21993676      PMCID: PMC3248945          DOI: 10.3324/haematol.2011.048918

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  21 in total

Review 1.  Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions.

Authors:  Leonard Leibovici; Mical Paul; Michael Cullen; Giampaolo Bucaneve; Anat Gafter-Gvili; Abigail Fraser; Winfried V Kern
Journal:  Cancer       Date:  2006-10-15       Impact factor: 6.860

2.  Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients.

Authors:  Anat Gafter-Gvili; Abigail Fraser; Mical Paul; Leonard Leibovici
Journal:  Ann Intern Med       Date:  2005-06-21       Impact factor: 25.391

Review 3.  Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials.

Authors:  Mical Paul; Dafna Yahav; Abigail Fraser; Leonard Leibovici
Journal:  J Antimicrob Chemother       Date:  2005-12-12       Impact factor: 5.790

Review 4.  Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.

Authors:  Johan Maertens
Journal:  Eur J Haematol       Date:  2007-01-23       Impact factor: 2.997

5.  A survey of the management of neutropenic fever in oncology units in the UK.

Authors:  H M Ziglam; K Gelly; W Olver
Journal:  Int J Antimicrob Agents       Date:  2007-02-12       Impact factor: 5.283

Review 6.  Additional anti-Gram-positive antibiotic treatment for febrile neutropenic cancer patients.

Authors:  M Paul; S Borok; A Fraser; L Vidal; M Cohen; L Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20

7.  Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia.

Authors:  J Styczynski; P Reusser; H Einsele; R de la Camara; C Cordonnier; K N Ward; P Ljungman; D Engelhard
Journal:  Bone Marrow Transplant       Date:  2008-12-01       Impact factor: 5.483

8.  A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation.

Authors:  Elio Castagnola; Vincenzo Fontana; Ilaria Caviglia; Silvia Caruso; Maura Faraci; Francesca Fioredda; Maria Luisa Garrè; Cristina Moroni; Massimo Conte; Giuseppe Losurdo; Franca Scuderi; Roberto Bandettini; Paolo Tomà; Claudio Viscoli; Riccardo Haupt
Journal:  Clin Infect Dis       Date:  2007-10-05       Impact factor: 9.079

Review 9.  The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Where do we go from here?

Authors:  Philip A Pizzo
Journal:  J Antimicrob Chemother       Date:  2009-05       Impact factor: 5.790

10.  Current antimicrobial usage for the management of neutropenic fever in Korea: a nationwide survey.

Authors:  Su-Mi Choi; Sun Hee Park; Dong-Gun Lee; Jung-Hyun Choi; Jin-Hong Yoo; Wan-Shik Shin
Journal:  J Korean Med Sci       Date:  2008-12-24       Impact factor: 2.153

View more
  5 in total

Review 1.  Antibiotic prophylaxis in children with cancer or who have undergone hematopoietic cell transplantation.

Authors:  V Cecinati; N Principi; L Brescia; S Esposito
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-07-26       Impact factor: 3.267

2.  Variation in Management of Fever and Neutropenia Among Pediatric Patients With Cancer: A Survey of Providers in Michigan.

Authors:  Emily L Mueller; Kelly J Walkovich; Gregory A Yanik; Sarah J Clark
Journal:  Pediatr Hematol Oncol       Date:  2015-06-18       Impact factor: 1.969

3.  Management of children with fever and neutropenia: results of a survey in 51 pediatric cancer centers in Germany, Austria, and Switzerland.

Authors:  Max Scheler; Thomas Lehrnbecher; Andreas H Groll; Ruth Volland; Hans-Jürgen Laws; Roland A Ammann; Philipp Agyeman; Andishe Attarbaschi; Margaux Lux; Arne Simon
Journal:  Infection       Date:  2020-06-10       Impact factor: 3.553

Review 4.  Update on infection control practices in cancer hospitals.

Authors:  Ella J Ariza-Heredia; Roy F Chemaly
Journal:  CA Cancer J Clin       Date:  2018-07-09       Impact factor: 508.702

5.  Reduced central line infection rates in children with leukemia following caregiver training: A quality improvement study.

Authors:  Andrea Lo Vecchio; Joshua K Schaffzin; Eliana Ruberto; Maria Angela Caiazzo; Loredana Saggiomo; Daniela Mambretti; Danila Russo; Sara Crispo; Grazia Isabella Continisio; Rossano Dello Iacovo; Vincenzo Poggi; Alfredo Guarino
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.